Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Zhaoke Ophthalmology's Days Payable or its related term are showing as below:
FRA:9FX'
s Days Payable Range Over the Past 10 Years
Min: 16.62 Med: 24.61 Max: 94.49
Current: 17.44
During the past 7 years, Zhaoke Ophthalmology's highest Days Payable was 94.49. The lowest was 16.62. And the median was 24.61.
FRA:9FX's Days Payable is ranked worse than 90.69% of 709
companies
in the Biotechnology industry
Industry Median: 111.24
vs FRA:9FX: 17.44
Zhaoke Ophthalmology's Days Payable
declined
from Dec. 2024 (15.16) to Dec. 2025 (12.18).
It may suggest that Zhaoke Ophthalmologyaccelerated paying its suppliers.
The historical data trend for Zhaoke Ophthalmology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:9FX vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Zhaoke Ophthalmology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Zhaoke Ophthalmology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhaoke Ophthalmology (FRA:9FX) has a Days Payable of 12.18 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhaoke Ophthalmology and its competitors. This is 51% below median its historical median of 24.61. Over the past decade, Zhaoke Ophthalmology's Days Payable has ranged from 16.62 to 94.49. According to the industry distribution chart, Zhaoke Ophthalmology ranks #643 out of 709 companies in the Biotechnology industry, placing it in the top 90.7%.
Is Zhaoke Ophthalmology's Days Payable too high?
Zhaoke Ophthalmology's current Days Payable of 12.18 is 51% below median its 10-year median of 24.61. Over the past 10 years, this metric has ranged from a low of 16.62 to a high of 94.49. The Biotechnology industry median Days Payable is 111.24. Zhaoke Ophthalmology's value of 12.18 is 89.1% below this industry median. Based on the distribution chart, Zhaoke Ophthalmology ranks #643 out of 709 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zhaoke Ophthalmology has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Zhaoke Ophthalmology's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhaoke Ophthalmology ranks #643 out of 709 companies for Days Payable. This places Zhaoke Ophthalmology in the lower half of its industry. The industry median Days Payable is 111.24. Zhaoke Ophthalmology's value of 12.18 is 89.1% below this benchmark. Historically, Zhaoke Ophthalmology's own Days Payable has ranged from 16.62 to 94.49 over the past decade. While the company's 10-year median is 24.61 vs. the industry median of 111.24, Zhaoke Ophthalmology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 709 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhaoke Ophthalmology's current Days Payable of 12.18 is 89.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhaoke Ophthalmology and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhaoke Ophthalmology's current Days Payable is 12.18, which is 51% below median its own 10-year median of 24.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhaoke Ophthalmology stock overvalued right now?
Zhaoke Ophthalmology (FRA:9FX) has a current Days Payable of 12.18. The stock's GF Value™ is €0.27, compared to a current price of €0.26 — trading 4.4% below its estimated fair value. The current Days Payable is 12.18, which is 51% below median its 10-year median of 24.61 and 89.1% below the Biotechnology industry median of 111.24. Zhaoke Ophthalmology's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhaoke Ophthalmology (FRA:9FX), the current Days Payable is 12.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhaoke Ophthalmology (FRA:9FX) Overvalued in 2026?
Based on GuruFocus' analysis, Zhaoke Ophthalmology stock appears to be undervalued.
The current stock price of €0.26 is trading 4.4% below its estimated GF Value™ of €0.27.
Key valuation signals for FRA:9FX:
Days Payable: 12.18 (51% below median its 10-year median of 24.61)
GF Value™: €0.27 vs. price of €0.26 (4.4% below fair value)
Industry Position: 89.1% below the Biotechnology median (#643 of 709)
No single metric tells the full story. See the FRA:9FX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company dedicated to the research, development, manufacture and commercialization of therapies that address unmet medical needs. The company has three flagship drug assets progressing towards potential market approval: NVK002 for myopia, CsA Ophthalmic Gel for DED and TAB014 for wAMD; and two drug assets in the clinical stage BRIMOCHOL PF for presbyopia and ZKY001 for corneal epithelial defects. Geographically the company operates in Hong Kong, Chinese Mainland, South Korea, and Others, of which it generates maximum revenue from Chinese Mainland.
47GF Score
Get the complete analysis for FRA:9FX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:9FX has been successfully added to your 
